Archive - Ninja Reports

Ninja Portfolio Update - 12/01/2024

Biotech Recovery in Full Swing

Dec 1, 2024 •

Investing Ninja

October 2024

MDGL - Earnings Preview

What to expect from MDGL in Nov

Oct 16, 2024 •

Investing Ninja

April 2024

Cytokinetics - Updated FOREST-HCM Data

Additional 48-week data from FOREST-HCM presented

Apr 6, 2024 •

Investing Ninja

Cytokinetics Summary

A New CV Drug in the Pipeline

Apr 4, 2024 •

Investing Ninja

February 2024

Spruce Biosciences Report

High Risk / High Reward Near Term Opportunity

Feb 20, 2024 •

Investing Ninja

Fairly valued with 2 launched products

Feb 13, 2024 •

Investing Ninja

November 2023

New Ninja Features

More tools to make you a better biotech investor

Nov 5, 2023 •

Investing Ninja

October 2023

XFOR Set For Major Moves

Expecting Additional CN Data at ASH

Oct 24, 2023 •

Investing Ninja

A Risky PDUFA Coming Up

Oct 12, 2023 •

Investing Ninja

US ALS Approval is a Significant Milestone

Oct 5, 2023 •

Investing Ninja

Madrigal Report

Disclaimer: Am long MDGL

Oct 1, 2023 •

Investing Ninja

September 2023

Introducing Ninja Reports

In-depth research on select biopharma companies

Sep 30, 2023 •

Investing Ninja

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts